An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

During September’s Prostate Cancer Awareness Month, MidLantic Urology is reminding men of a critical point. It's 0.75. If your PSA increases by 0.75 in 1 year, it could be prostate cancer, and it’s ...

As PSA testing recommendations change and the debate surrounding testing continues, people with a high-risk of prostate cancer and their families need to stay informed. John Salata says he is grateful ...

Please provide your email address to receive an email when new articles are posted on . At any given PSA level, Black men are more likely than white men to harbor prostate cancer, according to ...

A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...

Prostate-specific antigen (PSA) is a protein made by the prostate gland. A high PSA level could be a sign of an enlarged prostate, inflammation called prostatitis, or prostate cancer. The PSA test ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...